Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros











Intervalo de ano de publicação
1.
Rev. argent. microbiol ; Rev. argent. microbiol;52(1): 37-42, mar. 2020. graf
Artigo em Espanhol | LILACS | ID: biblio-1155683

RESUMO

Resumen Diversos estudios han evidenciado una resistencia cruzada entre isoniacida y etionamida, 2 de los fármacos utilizados en el tratamiento de la tuberculosis multirresistente.El objetivo del presente estudio fue determinar la resistencia cruzada entre ambos fármacos en aislados de Mycobacterium tuberculosis obtenidos en un hospital de Lima (Perú), conalta proporción de pacientes con tuberculosis. Se calculó la frecuencia de mutaciones asociadas con la resistencia a la isoniacida (INH) evaluando el gen katG y la región promotorainhA mediante la prueba molecular Genotype MTBDRplus v2.0. El método gold standard conocido como agar proporciones en placa (APP) permitió la identificación de resistencia a INH yetionamida. De 107 aislamientos resistentes a INH, 54 fueron multirresistentes (identificadosmediante la prueba Genotype MTBDRplus) y 49 (es decir, el 45,8% del total) también fueronresistentes a etionamida por el método APP. En los aislamientos resistentes a INH, se encontraron mutaciones en el gen katG en el 50,5% (54/107); en la región promotora inhA en el23,3% (25/107), y un 14,0% (15/107) presentaron mutaciones en ambos. Un 12,1% (13/107)fueron resistentes a INH por ausencia de banda wild type y banda de mutación. La mutaciónC-15T en la región promotora inhA presentó una fuerte asociación con la resistencia a etionamida y alcanzó el 73,4% (36/49) de los aislamientos resistentes a dicho fármaco. Los resultadosdel presente estudio sugieren que la identificación de mutaciones relacionadas con resistenciaa INH, sobre todo en la región promotora inhA, podría ser de gran utilidad para identificarla resistencia cruzada a etionamida y mejorar el tratamiento de las personas afectadas portuberculosis.© 2019 Asociacion Argentina de Microbiolog´ía. Publicado por Elsevier Espana, S.L.U. Este es unart´ículo Open Access bajo la licencia CC BY-NC-ND (https://creativecommons.org/licenses/by-nc-nd/4.0/).


Abstract Several studies have shown cross-resistance between isoniazid and ethionamide, 2of the drugs used in the treatment of multidrug-resistant tuberculosis. The objective of this study was to determine the cross-resistance between both drugs in Mycobacterium tuberculosis isolates from a hospital with high incidence of tuberculosis in Lima, Peru. The frequency of mutations to isoniazid in the katG gene and the inhA promoter region was identified by the Genotype MTBDRplus v2.0 molecular test. The gold standard Agar Proportion method (APM) allowed todetect resistance to isoniazid and ethionamide. Of 107 isoniazid-resistant isolates (54 multidrug-resistant isolates identified by the Genotype MTBDRplus test, 45.8% (49/107) were also resistant to ethionamide by the APM. Mutations were found in the katG gene in 50.5% (54/107), in the promoter region inhA in 23.3% (25/107) and 14.0% (15/107) that share both mutations in the resistant isolates to INH. The absence of the wild type and mutation bands indicated that 12.1% (13/107) of the isolates were resistant to INH. The mutation C-15T in the inhA promoter region showed a strong association with resistance to ethionamide in 73.4% (36/49) of the isolates analyzed. The results of the present study suggest that the identification of mutations related to resistance to isoniazid, especially in the inhA promoter region, could be very useful to identify cross-resistance to ethionamide and improve the treatment of individuals suffering from this disease.


Assuntos
Humanos , Tuberculose Resistente a Múltiplos Medicamentos/genética , Etionamida/farmacologia , Isoniazida/farmacologia , Mutação , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Antituberculosos/farmacologia , Peru , Interações Medicamentosas , Genótipo , Mycobacterium tuberculosis/isolamento & purificação
2.
Rev Argent Microbiol ; 52(1): 36-42, 2020.
Artigo em Espanhol | MEDLINE | ID: mdl-31255368

RESUMO

Several studies have shown cross-resistance between isoniazid and ethionamide, 2of the drugs used in the treatment of multidrug-resistant tuberculosis. The objective of this study was to determine the cross-resistance between both drugs in Mycobacterium tuberculosis isolates from a hospital with high incidence of tuberculosis in Lima, Peru. The frequency of mutations to isoniazid in the katG gene and the inhA promoter region was identified by the Genotype MTBDRplus v2.0 molecular test. The gold standard Agar Proportion method (APM) allowed todetect resistance to isoniazid and ethionamide. Of 107 isoniazid-resistant isolates (54 multidrug-resistant isolates identified by the Genotype MTBDRplus test, 45.8% (49/107) were also resistant to ethionamide by the APM. Mutations were found in the katG gene in 50.5% (54/107), in the promoter region inhA in 23.3% (25/107) and 14.0% (15/107) that share both mutations in the resistant isolates to INH. The absence of the wild type and mutation bands indicated that 12.1% (13/107) of the isolates were resistant to INH. The mutation C-15T in the inhA promoter region showed a strong association with resistance to ethionamide in 73.4% (36/49) of the isolates analyzed. The results of the present study suggest that the identification of mutations related to resistance to isoniazid, especially in the inhA promoter region, could be very useful to identify cross-resistance to ethionamide and improve the treatment of individuals suffering from this disease.


Assuntos
Antituberculosos/farmacologia , Etionamida/farmacologia , Isoniazida/farmacologia , Mutação , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/genética , Tuberculose Resistente a Múltiplos Medicamentos/genética , Interações Medicamentosas , Genótipo , Humanos , Mycobacterium tuberculosis/isolamento & purificação , Peru
3.
J Immunol Res ; 2015: 269610, 2015.
Artigo em Inglês | MEDLINE | ID: mdl-26064998

RESUMO

Autoimmune nephritis triggered by metallic ions was assessed in a Long-Evans rat model. The parameters evaluated included antinuclear autoantibody production, kidney damage mediated by immune complexes detected by immunofluorescence, and renal function tested by retention of nitrogen waste products and proteinuria. To accomplish our goal, the animals were treated with the following ionic metals: HgCl2, CuSO4, AgNO3, and Pb(NO3)2. A group without ionic metals was used as the control. The results of the present investigation demonstrated that metallic ions triggered antinuclear antibody production in 60% of animals, some of them with anti-DNA specificity. Furthermore, all animals treated with heavy metals developed toxic glomerulonephritis with immune complex deposition along the mesangium and membranes. These phenomena were accompanied by proteinuria and increased concentrations of urea. Based on these results, we conclude that metallic ions may induce experimental autoimmune nephritis.


Assuntos
Doenças Autoimunes/induzido quimicamente , Doenças Autoimunes/imunologia , Íons/efeitos adversos , Metais/efeitos adversos , Nefrite/induzido quimicamente , Nefrite/imunologia , Animais , Anticorpos Antinucleares/imunologia , Modelos Animais de Doenças , Imunofluorescência/métodos , Glomerulonefrite/induzido quimicamente , Glomerulonefrite/imunologia , Íons/imunologia , Rim/efeitos dos fármacos , Rim/imunologia , Glomérulos Renais/efeitos dos fármacos , Glomérulos Renais/imunologia , Masculino , Metais/imunologia , Proteinúria/imunologia , Ratos , Ratos Long-Evans
4.
Case Rep Genet ; 2013: 260371, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23653868

RESUMO

Fibrodysplasia ossificans progressiva (FOP) is an exceptionally rare genetic disease that is characterised by congenital malformations of the great toes and progressive heterotopic ossification (HO) in specific anatomical areas. This disease is caused by a mutation in activin receptor IA/activin-like kinase-2 (ACVR1/ALK2). A Mexican family with one member affected by FOP was studied. The patient is a 19-year-old female who first presented with symptoms of FOP at 8 years old; she developed spontaneous and painful swelling of the right scapular area accompanied by functional limitation of movement. Mutation analysis was performed in which genomic DNA as PCR amplified using primers flanking exons 4 and 6, and PCR products were digested with Cac8I and HphI restriction enzymes. The most informative results were obtained with the exon 4 flanking primers and the Cac8I restriction enzyme, which generated a 253 bp product that carries the ACVR1 617G>A mutation, which causes an amino acid substitution of histidine for arginine at position 206 of the glycine-serine (GS) domain, and its mutation results in the dysregulation of bone morphogenetic protein (BMP) signalling that causes FOP.

5.
Clin Dev Immunol ; 13(2-4): 163-6, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-17162359

RESUMO

In subacute cutaneous lupus eryhematosus (SCLE) the cutaneous antigens constitute the main source of Ro and La autoantigens. The aim of this investigation was to demonstrate if UV light increases the availability of Ro autoantigen in the skin, also the blocking effect of Ac-DEVD-CMK a caspase inhibitor was assessed. For this purpose newborn Balb/c mice were UVB irradiated (5-30 mJ/cm(2)) equivalent to a moderate to severe sunburn. Animals were injected with monoclonal anti-Ro antibodies from SCLE patients. Apoptosis was also induced by anti-Fas antibody injection. Skin samples were examined by direct immunofluoresence, by TUNEL, and the expression of caspase 3 by RT-PCR. Major findings of present studies were: 1. UVB irradiation and anti-Fas induced apoptosis of keratinocytes. 2. Apoptosis redistribute the Ro antigen on cell surface and is better triggered by Ro antibody. 3. The caspase 3 inhibitor Ac-DEVD-CMK decreases the availability of Ro autoantigen in epidermis and prevents deposition of anti-Ro. In conclusion, the caspase pathway would be blocked to avoid anti-Ro deposition along skin; this finding would be a prospect in the treatment of SCLE patients.


Assuntos
Apoptose , Autoanticorpos/administração & dosagem , Lúpus Eritematoso Cutâneo/metabolismo , Lúpus Eritematoso Cutâneo/patologia , Transtornos de Fotossensibilidade/etiologia , Ribonucleoproteínas/metabolismo , Raios Ultravioleta , Clorometilcetonas de Aminoácidos/farmacologia , Animais , Apoptose/fisiologia , Relação Dose-Resposta à Radiação , Lúpus Eritematoso Cutâneo/imunologia , Camundongos , Camundongos Endogâmicos BALB C , Ribonucleoproteínas/imunologia , Pele/efeitos dos fármacos , Pele/imunologia
6.
Cell Mol Biol Lett ; 11(3): 299-311, 2006.
Artigo em Inglês | MEDLINE | ID: mdl-16847561

RESUMO

Fas ligand (L) is a membrane protein from the tumor necrosis factor (TNF) family. It induces apoptosis upon contact with its Fas/CD95/APO1 receptor. Trimerization of FasL on the surface of effector cells is essential in the binding of the Fas trimer of the target cells. The receptor then recruits an adaptor and caspase-like proteins which lead apoptosis. This paper reports on the fate of FasL in HEp-2 cells committed to apoptosis by induction with campthotecin. Our main results demonstrated that in non-apoptotic cells, FasL aggregates in the cytoplasm forming trimers of 120 kDa. Apoptosis increases the trimeric FasL species, but also induces its dissociation into monomers of 35 kDa. In conclusion, camptothecin appears to perturb the Fas and FasL segregation in the cytoplasm by promoting the transit of FasL to the cell surface, thus fostering a process of autocrine or paracrine apoptosis. FasL is trimerized prior to Fas/FasL complex formation, and after apoptosis, FasL undergoes an intense turnover.


Assuntos
Apoptose/efeitos dos fármacos , Camptotecina/farmacologia , Proteína Ligante Fas/química , Proteína Ligante Fas/metabolismo , Clorometilcetonas de Aminoácidos/farmacologia , Caspase 3/genética , Linhagem Celular Tumoral , Fragmentação do DNA/efeitos dos fármacos , Desoxirribonucleases/genética , Proteína Ligante Fas/genética , Humanos , Marcação In Situ das Extremidades Cortadas , Proteínas de Ligação a Poli-ADP-Ribose , Estrutura Quaternária de Proteína , Transporte Proteico/efeitos dos fármacos , Frações Subcelulares/efeitos dos fármacos , Transcrição Gênica/efeitos dos fármacos , Receptor fas/genética
7.
Med Sci Monit ; 10(5): BR130-4, 2004 May.
Artigo em Inglês | MEDLINE | ID: mdl-15114260

RESUMO

BACKGROUND: Cajal bodies (CB) are distinct sub-nuclear domains rich in small nuclear ribonucleoprotein particles (snRNPs); they are involved in pre-mRNA processing. Lupus erythematosus (SLE) is an autoimmune disease characterized by autoantibody production against different nuclear molecules, including those involved in pre-mRNA processing. The aim of the present investigation is to assess the presence of anti-CB autoantibodies in a cohort of SLE sera. MATERIAL/METHODS: Antinuclear antibodies (ANA) were screened by indirect immunofluorescence in a batch of 190 sera from patients who met the ACR criteria for SLE classification; fine specificity was determined by Western blot using HEp-2 cells or rat hepatocyte extracts purified by ion exchange chromatography. RESULTS: Four sera had anti-Cajal body (CB) autoantibodies. Interestingly, all of these patients had intermittent extensive oral and esophageal ulceration. The autoantibodies to CB were of the IgG class, and by Western blot these sera had reactivity against an 80 kDa protein (coilin) associated with Sm proteins. CONCLUSIONS: Anti-CB autoantibodies constitute an uncommon specificity of SLE; therefore it seems that anti-CB antibody specificity is associated with extensive mucous ulceration.


Assuntos
Autoanticorpos/química , Corpos Enovelados/química , Corpos Enovelados/imunologia , Lúpus Eritematoso Sistêmico/imunologia , Adolescente , Adulto , Animais , Anticorpos Antinucleares/química , Western Blotting , Linhagem Celular , Cromatografia , Cromatografia por Troca Iônica , Estudos de Coortes , Feminino , Técnica Indireta de Fluorescência para Anticorpo , Hepatócitos/metabolismo , Humanos , Imunoglobulina G/química , Masculino , Pessoa de Meia-Idade , Estrutura Terciária de Proteína , RNA Mensageiro/metabolismo , Ratos
8.
Joint Bone Spine ; 70(3): 187-94, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12814761

RESUMO

OBJECTIVE: Present study addresses the issue whether cellular antigens recognised by antinuclear autoantibodies are driven by apoptosis. MATERIALS AND METHODS: HEp-2 cells were committed to apoptosis by camptothecin; DNA fragmentation and FasL and Bax expression monitored apoptosis. Autoantigens were probed by indirect immunofluorescence and Western blot with autoantibodies or monoclonals against: DNA, Ro60, La, U1-RNP, CENP-B, DNA Topoisomerase I, Jo-1 and NuMA. A comparison of antinuclear antibody reactivity between living and apoptotic cells was performed by ELISA. RESULTS: Apoptotic changes such as chromatin fragmentation, blebs and apoptotic bodies were induced with 20 mM camptothecin. Autoantigens were better detected in apoptotic cells. U1-RNP, Jo1, DNA-Topoisomerase I, CENP-B and NuMA exhibited fragmentation and redistribution as a consequence of apoptosis; in contrast, Ro60 and La ribonucleoproteins did not show proteolysis. Additionally the ELISA titers of antinuclear antibodies were higher in apoptotic cells than in normal cells. CONCLUSION: Apoptosis induces molecular changes in different autoantigens, this modification increases the antigen-driven response of autoantibodies such as anti-RNP, anti-DNA Topoisomerase I, anti-CENP-B and anti-Jo1. Apoptotic changes would contribute to break down the tolerance in autoimmune connective tissue disease.


Assuntos
Anticorpos Antinucleares/imunologia , Apoptose/imunologia , Autoantígenos/imunologia , Proteínas Proto-Oncogênicas c-bcl-2 , Apoptose/efeitos dos fármacos , Autoantígenos/metabolismo , Western Blotting , Camptotecina/farmacologia , Linhagem Celular , Fragmentação do DNA , Células Epiteliais/efeitos dos fármacos , Células Epiteliais/imunologia , Células Epiteliais/patologia , Proteína Ligante Fas , Técnica Indireta de Fluorescência para Anticorpo , Humanos , Glicoproteínas de Membrana/metabolismo , Proteínas Proto-Oncogênicas/metabolismo , Ribonucleoproteína Nuclear Pequena U1/imunologia , Proteína X Associada a bcl-2
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA